Hiccup for newly listed drug

Posted 12 June 2024 AM

CSL Seqirus is battling to iron out a potential speed bump in the supply of Korsuva, due to manufacturing issues, just as the chronic kidney disease (CKD) treatment starts its run on the PBS.

Korsuva is among a swathe of nephrology drugs that came out of CSL's $17.2 billion buyout of Vifor Pharma and is specifically used to treat moderate-to-severe pruritus associated with CKD in adults on haemodialysis.

To see the whole article, please login